Oyo State bets on WHO-backed contraceptive to close Nigeria's family planning gap

For anyone tracking where Africa's real wealth is built, the action is rarely in Lagos boardrooms. It is in primary health centres in Ibadan, where a quiet deal is taking shape that could reshape how millions of Nigerian women plan their families. Oyo State's Primary Healthcare Board has just opened talks with VIYA Health, the exclusive Nigerian distributor of a Bangladeshi-made contraceptive that carries the World Health Organization's prequalification seal. The meeting, held at the State Secretariat in Agodi, Ibadan, was about one product: Medogen SubQ, a subcutaneous injectable contraceptive produced by Incepta Pharmaceuticals. That WHO stamp matters more than any marketing budget. It tells health workers and patients that this is a product meeting stringent international standards for safety and efficacy, which is a far bigger deal than it sounds in a market where counterfeit and substandard medicines remain a persistent threat.

The numbers behind Nigeria's family planning deficit are stark, even if the source does not cite them. The country has one of the highest maternal mortality rates in the world, and unmet need for contraception remains a driver of that tragedy. What the source does tell us is that Oyo State's Executive Secretary, physician Muideen Olatunji, welcomed the engagement with the enthusiasm of a man who has been waiting for options. His message was simple: the state is open to innovative programmes, committed to investing in health commodities, and sees expanding access to affordable contraceptives through primary health centres as a direct route to better maternal and child health outcomes. That is not just bureaucratic language. In a country where most women deliver outside health facilities, getting contraception to the last mile through primary health centres is a logistical triumph waiting to happen.

VIYA Health's business lead, pharmacist Billy Shoaga, framed the collaboration as part of a broader push to work with state governments. But the real story is the business model. Incepta, a Dhaka-based pharmaceutical giant, produces Medogen SubQ at a price point that makes it viable for public-sector distribution. VIYA Health, as exclusive distributor, is betting that scale will beat margin. The company is essentially inserting itself into a supply chain that has historically been dominated by donor-funded programmes and international NGOs. By partnering directly with state governments, VIYA Health is tapping into Nigeria's decentralised health budget, a strategy that could prove more sustainable than relying on foreign aid that ebbs and flows with geopolitical whims.

This deal also signals something about the direction of African health commerce. For years, the continent has been a dumping ground for cheap drugs from India and China, often of dubious quality. The WHO prequalification of a Bangladeshi product distributed by a Nigerian company flips that narrative. It shows that south-south trade can deliver quality, not just low cost. Oyo State is not just buying a contraceptive; it is buying assurance. And for a state government that has to answer to voters who are tired of empty clinics, that assurance is worth real political capital. The fact that Olatunji explicitly mentioned investing in health commodities suggests Oyo is willing to put its own budget where its mouth is, rather than waiting for federal intervention or foreign donors.

Looking ahead, the success of this partnership could become a template. If Oyo State can demonstrate improved uptake and better health outcomes, other Nigerian states will follow. The country's primary healthcare system is chronically underfunded, but it is also the only system that reaches the rural poor. A WHO-prequalified product, distributed through that system, at a price the government can afford, is a rare alignment of interests. The private sector gets a reliable buyer, the government gets a credible product, and women get a choice. That is the kind of deal that does not make headlines in financial papers, but it moves the needle on the continent's most stubborn development indicators. For now, the talks are just talks. But in the world of African health economics, this is as close to a breakthrough as it gets.